European Stocks Slip as U.S.-Iran Tensions and Earnings Season Weigh on Markets 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Iraq Reaffirms Commitment to OPEC as UAE Exits Amid Global Energy Tensions 
Australia Inflation Surges in March as Fuel Prices Spike Amid Middle East Conflict 
Wall Street Futures Rise as Trump Discusses Iran’s Hormuz Strait Proposal and Tech Earnings Loom 
Trump Rejects Iran Proposal as War Tensions Push Oil Prices Higher 
Asian Stocks Mixed as BOJ Holds Rates, Oil Prices and Fed Outlook Weigh on Markets 
Oil Prices Slip Amid UAE’s OPEC Exit and Ongoing Iran Conflict Concerns 
Ukraine Faces Pressure to Introduce VAT on Low-Value Imports to Secure IMF Funding 
Gold Prices Drop Amid Iran War Concerns, Rising Oil Costs, and Hawkish Central Bank Signals 
Kevin Warsh Advances Toward Fed Chair Role Amid Political Tensions 
Gold Prices Fall as Strong Dollar and Rising Oil Prices Pressure Markets 
Bank of England Set to Hold Interest Rates as Inflation Risks and Iran War Impact Loom 
Trump-Iran Conflict Escalates as Nuclear Talks Stall and Oil Prices Surge 
Asian Markets Mixed as Fed Decision, Iran Tensions, and Inflation Data Weigh on Sentiment 
Trump Urges Iran to Sign Nuclear Deal Amid Ongoing Conflict and Port Blockade 
Trump Urges Iran to Call for Talks as War Stalemate Disrupts Oil Markets 
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
